pacific biosciences of california inc. - PACB

PACB

Close Chg Chg %
1.73 0.14 8.09%

Closed Market

1.87

+0.14 (8.09%)

Volume: 7.07M

Last Updated:

Dec 31, 2025, 4:00 PM EDT

Company Overview: pacific biosciences of california inc. - PACB

PACB Key Data

Open

$1.76

Day Range

1.75 - 1.88

52 Week Range

0.85 - 2.73

Market Cap

$564.57M

Shares Outstanding

301.91M

Public Float

270.83M

Beta

2.20

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.69

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

6.39M

 

PACB Performance

1 Week
 
5.65%
 
1 Month
 
-21.76%
 
3 Months
 
25.50%
 
1 Year
 
2.19%
 
5 Years
 
-92.79%
 

PACB Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 10
Full Ratings ➔

About pacific biosciences of california inc. - PACB

Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: America, Europe, Middle East, and Africa, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.

PACB At a Glance

Pacific Biosciences of California, Inc.
1305 O'Brien Drive
Menlo Park, California 94025
Phone 1-650-521-8000 Revenue 154.01M
Industry Medical Specialties Net Income -309,851,000.00
Sector Health Technology Employees 575
Fiscal Year-end 12 / 2025
View SEC Filings

PACB Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 3.426
Price to Book Ratio 1.064
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -3.827
Enterprise Value to Sales 5.27
Total Debt to Enterprise Value 0.831

PACB Efficiency

Revenue/Employee 267,850.435
Income Per Employee -538,871.304
Receivables Turnover 5.596
Total Asset Turnover 0.102

PACB Liquidity

Current Ratio 7.476
Quick Ratio 6.59
Cash Ratio 5.892

PACB Profitability

Gross Margin 15.373
Operating Margin -172.349
Pretax Margin -200.978
Net Margin -201.184
Return on Assets -20.612
Return on Equity -51.304
Return on Total Capital -26.231
Return on Invested Capital -22.179

PACB Capital Structure

Total Debt to Total Equity 133.171
Total Debt to Total Capital 57.113
Total Debt to Total Assets 53.523
Long-Term Debt to Equity 130.757
Long-Term Debt to Total Capital 56.078
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Pacific Biosciences Of California Inc. - PACB

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
130.51M 128.30M 200.52M 154.01M
Sales Growth
+65.43% -1.69% +56.29% -23.19%
Cost of Goods Sold (COGS) incl D&A
71.73M 79.45M 160.18M 130.34M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
11.59M 17.32M 32.69M 53.34M
Depreciation
11.20M 16.41M 18.27M 25.94M
Amortization of Intangibles
381.00K 913.00K 14.42M 27.40M
COGS Growth
+54.83% +10.76% +101.61% -18.63%
Gross Income
58.78M 48.85M 40.34M 23.68M
Gross Income Growth
+80.51% -16.89% -17.42% -41.32%
Gross Profit Margin
+45.04% +38.08% +20.12% +15.37%
2021 2022 2023 2024 5-year trend
SG&A Expense
236.95M 353.67M 350.71M 289.12M
Research & Development
112.90M 193.00M 187.17M 129.02M
Other SG&A
124.05M 160.67M 163.54M 160.09M
SGA Growth
+73.02% +49.26% -0.84% -17.56%
Other Operating Expense
- - - -
-
Unusual Expense
32.27M 2.38M 26.14M 54.47M
EBIT after Unusual Expense
(210.44M) (307.20M) (336.50M) (319.91M)
Non Operating Income/Expense
(51.91M) 7.64M 32.68M 23.78M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
12.53M 14.69M 14.34M 13.41M
Interest Expense Growth
+4,592.88% +17.24% -2.36% -6.49%
Gross Interest Expense
12.53M 14.69M 14.34M 13.41M
Interest Capitalized
- - - -
-
Pretax Income
(274.87M) (314.25M) (318.16M) (309.54M)
Pretax Income Growth
-1,034.84% -14.33% -1.24% +2.71%
Pretax Margin
-210.61% -244.92% -158.67% -200.98%
Income Tax
- (93.65M) (11.42M) 316.00K
Income Tax - Current - Domestic
- - - 521.00K
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - (11.42M) (205.00K)
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(181.22M) (314.25M) (306.74M) (309.85M)
Minority Interest Expense
- - - -
-
Net Income
(181.22M) (314.25M) (306.74M) (309.85M)
Net Income Growth
-716.34% -73.40% +2.39% -1.02%
Net Margin Growth
-138.85% -244.92% -152.97% -201.18%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(181.22M) (314.25M) (306.74M) (309.85M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(181.22M) (314.25M) (306.74M) (309.85M)
EPS (Basic)
-0.8878 -1.3995 -1.2094 -1.1288
EPS (Basic) Growth
-598.76% -57.64% +13.58% +6.66%
Basic Shares Outstanding
204.14M 224.55M 253.63M 274.49M
EPS (Diluted)
-0.8878 -1.3995 -1.2094 -1.5877
EPS (Diluted) Growth
-628.45% -57.64% +13.58% -31.28%
Diluted Shares Outstanding
204.14M 224.55M 253.63M 288.37M
EBITDA
(166.58M) (287.50M) (277.67M) (212.10M)
EBITDA Growth
-75.20% -72.59% +3.42% +23.61%
EBITDA Margin
-127.63% -224.08% -138.48% -137.72%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 2.25
Number of Ratings 10 Current Quarters Estimate -0.143
FY Report Date 03 / 2026 Current Year's Estimate -0.533
Last Quarter’s Earnings -0.14 Median PE on CY Estimate N/A
Year Ago Earnings -1.847 Next Fiscal Year Estimate -0.467
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 6 7 7 7
Mean Estimate -0.14 -0.13 -0.53 -0.47
High Estimates -0.13 -0.12 -0.50 -0.38
Low Estimate -0.17 -0.14 -0.57 -0.51
Coefficient of Variance -9.53 -5.85 -4.94 -10.38

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 4 4 4
OVERWEIGHT 0 0 1
HOLD 6 6 7
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Pacific Biosciences Of California Inc. - PACB

Date Name Shares Transaction Value
Apr 15, 2025 James R. Gibson See Remarks 1,000,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 15, 2025 James R. Gibson See Remarks 2,000,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 24, 2025 Christian O. Henry See Remarks 3,146,167 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 24, 2025 Christian O. Henry See Remarks 1,841,621 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 24, 2025 Mark David van Oene See Remarks 1,946,871 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 24, 2025 Mark David van Oene See Remarks 898,352 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 24, 2025 Michele Farmer See Remarks 274,454 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 24, 2025 Michele Farmer See Remarks 179,670 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Pacific Biosciences Of California Inc. in the News